2024-512330-15-00暂停1 期
Phase I, first-in-man, randomised, placebo-controlled, single dose escalation study to investigate the effects of LPH-5 on safety, tolerability, pharmacokinetic and pharmacodynamic parameters in healthy participants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- Lophora ApS
- 入组人数
- 56
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Drug Development Associate
Scientific
Lophora ApS
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Phase I, single-centre, randomised, placebo-controlled, double-blinded study, with single ascending dose and multiple dose at maximum tolerated dose, evaluating the safety, tolerability and pharmacokinetics of ALX-0171, administered by pulmonary inhalation, in healthy male volunteersvirus that infect the airwaysrespiratory syncytial virus infection1004743810024970NL-OMON37342Ablynx NV100
进行中（未招募）
1 期
Study for patients with relapsed, refractory, incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives).relapsed, refractory, incurable teratomaEUCTR2014-000428-12-FRovartis Pharma Services AG90
进行中（未招募）
1 期
Study for patients with relapsed, refractory, incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives).EUCTR2014-000428-12-NLovartis Pharma Services AG42
进行中（未招募）
1 期
Study for patients with relapsed, refractory,incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives)EUCTR2014-000428-12-ITOVARTIS FARMA S.P.A.10
进行中（未招募）
不适用
Study for patients with relapsed, refractory, incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives).relapsed, refractory, incurable teratomaMedDRA version: 18.0Level: PTClassification code 10043276Term: TeratomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000428-12-DKovartis Pharma Services AG42